ANDA 218838, held by Micro Labs. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 218838 (Valganciclovir Hydrochloride), held by Micro Labs, was first approved by FDA on Mar 19, 2026, with 0 approved supplements and 0 published complete response letters.
Valganciclovir is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Pediatric Patients Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.2 Pediatric Patients Prevention of CMV Disease: Valganciclovir for oral solution is indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 19, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir Hydrochloride50MG/ML · for solution;oral | Valganciclovir Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters